Jakub Karwacki, Laura Wojdyło, Karolina Klasen, Andrzej Dłubak, Adam Gurwin, Maciej Kaczorowski, Agnieszka Hałoń, Wojciech Krajewski, Tomasz Szydełko, Bartosz Małkiewicz
{"title":"回顾淋巴血管侵袭在前列腺癌中的作用。","authors":"Jakub Karwacki, Laura Wojdyło, Karolina Klasen, Andrzej Dłubak, Adam Gurwin, Maciej Kaczorowski, Agnieszka Hałoń, Wojciech Krajewski, Tomasz Szydełko, Bartosz Małkiewicz","doi":"10.1016/j.urology.2025.06.063","DOIUrl":null,"url":null,"abstract":"<p><p>Lymphovascular invasion (LVI) is an adverse histopathological marker in prostate cancer (PCa), associated with increased risks of disease progression and biochemical recurrence (BCR). Despite its established value as an independent predictive factor, LVI remains underutilized in clinical decision-making. In particular, LVI identified in radical prostatectomy specimens does not currently influence management strategies, even though numerous studies highlight its critical role in patient outcomes. This review synthesizes recent literature on the clinical significance of LVI in PCa, emphasizing its relationship with BCR, lymph node invasion (LNI), and survival parameters. Future directions highlight the need for larger prospective studies, standardized definitions, and artificial intelligence-driven histopathological tools to enhance the detection and integration of LVI into clinical practice.</p>","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Revisiting the role of lymphovascular invasion in prostate cancer: a narrative review.\",\"authors\":\"Jakub Karwacki, Laura Wojdyło, Karolina Klasen, Andrzej Dłubak, Adam Gurwin, Maciej Kaczorowski, Agnieszka Hałoń, Wojciech Krajewski, Tomasz Szydełko, Bartosz Małkiewicz\",\"doi\":\"10.1016/j.urology.2025.06.063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lymphovascular invasion (LVI) is an adverse histopathological marker in prostate cancer (PCa), associated with increased risks of disease progression and biochemical recurrence (BCR). Despite its established value as an independent predictive factor, LVI remains underutilized in clinical decision-making. In particular, LVI identified in radical prostatectomy specimens does not currently influence management strategies, even though numerous studies highlight its critical role in patient outcomes. This review synthesizes recent literature on the clinical significance of LVI in PCa, emphasizing its relationship with BCR, lymph node invasion (LNI), and survival parameters. Future directions highlight the need for larger prospective studies, standardized definitions, and artificial intelligence-driven histopathological tools to enhance the detection and integration of LVI into clinical practice.</p>\",\"PeriodicalId\":23415,\"journal\":{\"name\":\"Urology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urology.2025.06.063\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urology.2025.06.063","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Revisiting the role of lymphovascular invasion in prostate cancer: a narrative review.
Lymphovascular invasion (LVI) is an adverse histopathological marker in prostate cancer (PCa), associated with increased risks of disease progression and biochemical recurrence (BCR). Despite its established value as an independent predictive factor, LVI remains underutilized in clinical decision-making. In particular, LVI identified in radical prostatectomy specimens does not currently influence management strategies, even though numerous studies highlight its critical role in patient outcomes. This review synthesizes recent literature on the clinical significance of LVI in PCa, emphasizing its relationship with BCR, lymph node invasion (LNI), and survival parameters. Future directions highlight the need for larger prospective studies, standardized definitions, and artificial intelligence-driven histopathological tools to enhance the detection and integration of LVI into clinical practice.
期刊介绍：
Urology is a monthly, peer–reviewed journal primarily for urologists, residents, interns, nephrologists, and other specialists interested in urology
The mission of Urology®, the "Gold Journal," is to provide practical, timely, and relevant clinical and basic science information to physicians and researchers practicing the art of urology worldwide. Urology® publishes original articles relating to adult and pediatric clinical urology as well as to clinical and basic science research. Topics in Urology® include pediatrics, surgical oncology, radiology, pathology, erectile dysfunction, infertility, incontinence, transplantation, endourology, andrology, female urology, reconstructive surgery, and medical oncology, as well as relevant basic science issues. Special features include rapid communication of important timely issues, surgeon''s workshops, interesting case reports, surgical techniques, clinical and basic science review articles, guest editorials, letters to the editor, book reviews, and historical articles in urology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
